VYALEV® (foscarbidopa and foslevodopa), the VYAFUSER Pump, and Related Infusion Supplies - Correct Coding and Billing - Revised

VYALEV® (foscarbidopa and foslevodopa, AbbVie Inc. Chicago, IL, U.S.A) is a medication approved by the U.S. Food and Drug Administration on October 17, 2024, and is indicated for the treatment of motor fluctuations in adults with advanced Parkinson's disease.